Media release Feb 02, 2024

DINAMIQS Appoints New CEO and Board Member

  • Martin Kessler, formerly Chief Transformation Officer at Rentschler, will become Chief Executive Officer of DINAMIQS, effective 1 March 2024.
  • Eduard Ayuso, currently CEO, ¬†will become Chief Technology Officer.
  • Manja Boerman, formerly President Cell, Gene and Protein Therapy at Catalent, joins as a new independent board member.

Martin Kessler will take over the role as Chief Executive Officer of DINAMIQS as of 1 March 2024. He joins from Rentschler Biopharma SE, where he was Chief Transformation Officer and previously CEO of Rentschler’s US biopharma business. In this role he also led Rentschler’s largest expansion project and the construction of a brand new CDMO facility. Prior to that, he led the medical products operations service line in Europe at McKinsey & Company. Martin Kessler holds a Ph.D. in engineering from the Berlin Institute of Technology (Germany).

Eduard Ayuso, who led DINAMIQS as CEO since its inception, will become Chief Technology Officer. Together, Martin and Eduard will drive the future development of DINAMIQS and successfully position Siegfried in the strongly growing Cell & Gene Therapy space.

Manja Boerman joins DINAMIQS as an independent and non-executive member and will strengthen DINAMIQS’ Board of Directors with her extensive experience in biologics and cell and gene therapies. Until the end of 2023, she served as President Cell, Gene and Protein Therapy at Catalent Pharma Solutions in Somerset, NJ (US), after having held several positions with increasing responsibility at Catalent since 2019. Before joining Catalent, she worked, amongst others, as Executive Director for the global biologics business of Charles Rivers Laboratories in Boston (US) and as President Pharmaceuticals at Aesica Pharmaceuticals in Hemel Hempstead (UK). Manja Boerman holds a Ph.D. in Biochemistry from the State University in Buffalo (US).

Eduard Ayuso:”Manja and Martin bring a wealth of knowledge in their respective fields to DINAMIQS. I look forward to working in collaboration to develop the company to the next level of growth.”

Martin Kessler:”I am eager to join the talented DINAMIQS team. Together, and with our unique value proposition, we will build DINAMIQS into a leading CDMO in the Cell & Gene Therapy space.”


DINAMIQS, a Siegfried company, is a science-driven Contract Development and Manufacturing Organization (CDMO) offering end-to-end viral vector manufacturing solutions. DINAMIQS offers a comprehensive and customized range of manufacturing services, process development, quality control and analytics solutions for genetic medicine companies. It is located in Schlieren-Zurich Bio-Technopark in Switzerland.

To top